Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 5/20 | 0.51 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2972649 | 0.85 | MAPT (0.60) | MAPTCYP2A6KEAP1KIF11MEN1 | |
| SCHEMBL2600053 | 0.82 | CYP2A6 (0.55) | MAPTCYP2A6KEAP1KIF11AXL | |
| SCHEMBL22330405 | 0.81 | KIF11 (0.50) | MAPTKIF11HRH4MEN1KMT2A | |
| SCHEMBL22185221 | 0.79 | GRM1 (0.57) | MAPTKIF11HRH4MEN1KMT2A | |
| SCHEMBL27290612 | 0.77 | HRH4 (0.47) | KIF11HRH4MEN1KMT2AKDM4E | |
| SCHEMBL12777894 | 0.77 | KIF11 (0.44) | MAPTKIF11HRH4MEN1KMT2A | |
| SCHEMBL22996085 | 0.77 | NR3C1 (0.45) | KIF11HRH4MEN1KMT2AKDM4E | |
| SCHEMBL6092073 | 0.77 | CYP2A6 (0.49) | MAPTCYP2A6KEAP1AXLMEN1 | |
| SCHEMBL13463363 | 0.77 | CYP2A6 (0.49) | MAPTCYP2A6KEAP1AXLMEN1 | |
| SCHEMBL2534572 | 0.77 | HRH4 (0.44) | MAPTKIF11HRH4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109926-A1 | SPIROOXINDOLE COMPOUND AND USE THEREOF IN PREPARATION OF PROTEASE INHIBITOR AS ANTIVIRAL DRUG | 南京药石科技股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210047293-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-18 | — | — | US | disclosed |
| WO-2019157417-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019046318-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| CN-104583208-B | Can be used for treating substituted 3,4-dihydro-2H-pyrido [1,2-a] pyrazine-1,6-derovatives of (especially) Alzheimer | 杨森制药公司 | 2016-09-28 | — | — | CN | disclosed |
| EP-2850083-B1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | JANSSEN PHARMACEUTICALS INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-9181245-B2 | Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease | Janssen Pharmaceuticals, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | CELLZOME LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| CN-104583208-A | Substituted 3, 4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives useful for the treatment of (inter alia) alzheimer's disease | JANSSEN PHARMACEUTICALS INC | 2015-04-29 | — | — | CN | disclosed |
| EP-2850083-A1 | SUBSTITUTED 3, 4 - DIHYDRO - 2H - PYRIDO [1, 2 -A]PYRAZINE - 1, 6 - DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | Janssen Pharmaceuticals, Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| CN-103502237-A | FAAH inhibitors | IRONWOOD PHARMACEUTICALS INC | 2014-01-08 | — | — | CN | disclosed |
| WO-2013171712-A1 | SUBSTITUTED 3, 4 - DIHYDRO - 2H - PYRIDO [1, 2 -A] PYRAZINE - 1, 6 - DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | Janssen Pharmaceuticals, Inc. (US) | 2013-11-21 | — | — | WO | disclosed |
| US-8093278-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20100210685-A1 | Novel Substituted Indoles | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7754735-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1549634-A1 | NOVEL SUBSTITUTED INDOLES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2003101981-A1 | NOVEL SUBSTITUTED INDOLES | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| US-4026931-A | AZO DYES, FIBER-REACTIVE; INDOLE OR 5-AMINO-PYRAZOLE COUPLING COMPONENT | BAYER AKTIENGESELLSCHAFT (DT) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210685-A1 | Novel Substituted Indoles | IDO1, IDO2, TPH1 | MAPT 2642/4885CYP2A6 181/4885KEAP1 410/4885 |
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | P2RY14, P2RY1, P2RY13 | MAPT 4884/4885CYP2A6 2337/4885KEAP1 2505/4885 |
| US-20210047293-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | P2RY14, P2RY1, P2RY13 | MAPT 4884/4885CYP2A6 2337/4885KEAP1 2505/4885 |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | HRH2, HRH1, HCAR2 | MAPT 4719/4885CYP2A6 1761/4885KEAP1 739/4885 |
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | BACE1, PSEN1, BACE2 | MAPT 127/4885CYP2A6 390/4885KEAP1 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.